Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease

(2011) Joo-Ho Shin et al.   CELL

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

(2011) Olivier Rascol et al.   LANCET NEUROLOGY

Parkinson's syndrome and Parkinson's disease in mitochondrial disorders

(2011) Josef Finsterer   MOVEMENT DISORDERS

Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

(2010) Tamar Goren et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson’s subject mitochondrial transfer

(2010) A. Raquel Esteves et al.   JOURNAL OF NEUROCHEMISTRY

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

(2010) K.Y. Chau et al.   NEUROCHEMISTRY INTERNATIONAL

Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2

(2010) H. Mortiboys et al.   NEUROLOGY

Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction?

(2010) J. E. Ahlskog et al.   NEUROLOGY

The delayed-start study in Parkinson disease: Can't satisfy everyone

(2010) C. W. Olanow et al.   NEUROLOGY

PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease

(2010) B. Zheng et al.   Science Translational Medicine

PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin

(2010) Derek P. Narendra et al.   PLOS BIOLOGY

Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease

(2009) Venkatesh Atul Bhattaram et al.   AAPS Journal

Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease

(2009) Elke Hattingen et al.   BRAIN

Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?

(2009) E. Kirches   CURRENT GENOMICS

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease

(2009) Makoto Naoi et al.   Expert Review of Neurotherapeutics

Mitochondrial accumulation of polyubiquitinated proteins and differential regulation of apoptosis by polyubiquitination sites Lys-48 and -63

(2009) Faneng Sun et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

(2009) Orit Bar-Am et al.   JOURNAL OF NEUROCHEMISTRY

Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle

(2009) Kristen A Malkus et al.   Molecular Neurodegeneration

Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis

(2009) Shawna Tazik et al.   NEUROTOXICITY RESEARCH

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study

(2009) A. Schapira et al.   PARKINSONISM & RELATED DISORDERS

PINK1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit and α-Synuclein Aggregation in Cell Culture Models of Parkinson's Disease

(2009) Wencheng Liu et al.   PLoS One

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

(2008) Wen Zhu et al.   JOURNAL OF NEUROCHEMISTRY

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

(2008) C. Warren Olanow et al.   MOVEMENT DISORDERS

Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis

(2008) Nilkantha Sen et al.   NATURE CELL BIOLOGY

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy

(2007) Nadia Stefanova et al.   EXPERIMENTAL NEUROLOGY